comparemela.com

Latest Breaking News On - Head of biopharma development - Page 3 : comparemela.com

Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive topline results from the Phase 3b.

Naoki okamuraAstellas pharma incPrnewswire astellas pharma incHead of biopharma developmentHealth qual life outcomesDrug administrationVice presidentBiopharma developmentPrescribing informationPatient product informationArea approachEqual lifeAstellas pharma inc

Astellas VEOZAH™ (fezolinetant) Approved by U S FDA for Treatment of Vasomotor Symptoms Due to Menopause

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA).

United statesAstellas pharmaNaoki okamuraGenevieve neal perryDrug administrationJ public healthAstellas pharma incAstellas incHead of biopharma developmentSchool of medicine department obstetricsPrnewswire astellas pharma incHealth qual life outcomesFull interactive multimediaMedicine departmentMarci englishVice president

Astellas VEOZAH™ (fezolinetant) Approved by U S FDA for Treatment of Vasomotor Symptoms Due to Menopause

VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause TOKYO, May 12, 2023 /PRNewswire/ Astellas Pharma Inc. today. | June 14, 2023

United statesGenevieve neal perryNaoki okamuraAstellas pharmaPrnewswire astellas pharma incHealth qual life outcomesSchool of medicine department obstetricsAstellas pharma incJ public healthDrug administrationAstellas incHead of biopharma developmentFull interactive multimediaMedicine departmentMarci englishVice president

vimarsana © 2020. All Rights Reserved.